Phase I/IIa, Open-Labeled, Dose Escalation Clinical Study Using FGF-2 Gene Mounted Sendai Virus Vector for Critically Ischemic Limbs

被引：0
|
作者：
Matsumoto, Takuya [1 ]
Yonemitsu, Yoshikazu [1 ]
Itoh, Hiroyuki [1 ]
Okazaki, Jin [1 ]
Uchiyama, Makiko [1 ]
Yoshida, Kumi [1 ]
Onohara, Toshihiro [1 ]
Hiroyuki, Inoguchi [1 ]
Kyuragi, Ryoichi [1 ]
Guntani, Atsushi [1 ]
Shimokawa, Mototsugu [1 ]
Onimaru, Mitsuho [1 ]
Ban, Hiroshi [1 ]
Makoto, Inoue [1 ]
Zhu, Tsugumine [1 ]
Hasegawa, Mamoru [1 ]
Nakanishi, Yoichi [1 ]
Maehara, Yoshihiko [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan
来源：
JOURNAL OF GENE MEDICINE | 2014年 / 16卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
S6-5
引用
收藏
页码：211 / 212
页数：2
相关论文
共 12 条
  • [1] Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
    Laham, RJ
    Chronos, NA
    Pike, M
    Leimbach, ME
    Udelson, JE
    Pearlman, JD
    Pettigrew, RI
    Whitehouse, MJ
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) : 2132 - 2139
  • [2] A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
    Chu, Quincy Siu-Chung
    Sangha, Randeep
    Spratlin, Jennifer
    Vos, Larissa J.
    Mackey, John R.
    McEwan, Alexander J. B.
    Venner, Peter
    Michelakis, Evangelos D.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 603 - 610
  • [3] A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
    Quincy Siu-Chung Chu
    Randeep Sangha
    Jennifer Spratlin
    Larissa J. Vos
    John R. Mackey
    Alexander J. B. McEwan
    Peter Venner
    Evangelos D. Michelakis
    Investigational New Drugs, 2015, 33 : 603 - 610
  • [4] Current status of clinical development for gene therapy with Sendai virus vector expressing the human FGF-2 gene (DVC1-0101) to treat peripheral arterial disease
    Tanaka, M.
    Yonemitsu, Y.
    HUMAN GENE THERAPY, 2018, 29 (12) : A137 - A137
  • [5] Current Status of Clinical Development for Gene Therapy with Sendai Virus Vector Expressing the Human Fgf-2 Gene (Dvc1-0101) to Treat Peripheral Arterial Disease
    Tanaka, Michiko
    Harada, Yui
    Yonemitsu, Yoshikazu
    MOLECULAR THERAPY, 2018, 26 (05) : 350 - 350
  • [6] An Update Progress Report of Clinical Safety and Efficacy for Gene Therapy with Sendai Virus Vector Expressing the Human FGF-2 Gene (DVC1-0101) to Treat Peripheral Arterial Disease
    Tanaka, Michiko
    Harada, Yui
    Yonemitsu, Yoshikazu
    MOLECULAR THERAPY, 2019, 27 (04) : 249 - 250
  • [7] Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.
    Huang, Jing
    Zhang, Bo
    Tang, Jialin
    Chang, Qing
    Zhang, Rui
    Geng, Chengyun
    Wu, Dawei
    Qi, Ling
    Gu, Xiangyong
    Liu, Binlei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study
    Lien, Chia En
    Liu, Ming-Che
    Wang, Ning-Chi
    Liu, Luke Tzu-Chi
    Wu, Chung-Chin
    Tang, Wei-Hsuan
    Lian, Wei-Cheng
    Huang, Kuan-Ying A.
    Chen, Charles
    VACCINES, 2023, 11 (12)
  • [9] TEM-GBM: an open-label, Phase I/IIa dose-escalation study evaluating the safety and efficacy of genetically modified Tie-2 expressing monocytes to deliver IFN-a within glioblastoma tumor microenvironment
    Gentner, B.
    Capotondo, A.
    Eoli, M.
    Farina, F.
    Anghileri, E.
    Ferla, V.
    Carrabba, M. G.
    Cuccarini, V.
    Garramone, M.
    Di Meco, F.
    Legnani, F.
    Pollo, B.
    Saini, M.
    Ferroli, P.
    Pallini, R.
    D'Alessandris, G.
    Patane, M.
    Paterra, R.
    Brambilla, V.
    Magnani, T.
    Antonarelli, G.
    Naldini, M. M.
    Barcella, M.
    Mazzoleni, S.
    Bashir, Z.
    Olivi, A.
    Bruzzone, M. G.
    Russo, C.
    Ciceri, F.
    Finocchiaro, G.
    Naldini, L.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A90 - A90
  • [10] Results of a phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (Pts) with severe ischemic heart disease: 6 months follow-up
    Laham, RJ
    Chronos, NA
    Leimbach, M
    Pearlman, JD
    Pettigrew, R
    Dilsizian, V
    Udelson, J
    Whitehouse, MJ
    Pike, M
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 73A - 73A
12